682771-68-2

Upstream product

• 100-39-0 benzyl bromide 
• 682771-65-9 3,4-di-O-benzyl-2-C-benzyloxymethyl-6-O-tert-butyldimethylsilyl-1,2,5-trideoxy-1,5-imino-D-glucitol 
• 682771-67-1 N-benzyl-3,4-di-O-benzyl-2-C-benzyloxymethyl-1,2,5-trideoxy-1,5-imino-D-glucitol 
• 682771-66-0 N-benzyl-3,4-di-O-benzyl-2-C-benzyloxymethyl-6-O-tert-butyldimethylsilyl-1,2,5-trideoxy-1,5-imino-D-glucitol 
• 682771-59-1 3,4-di-O-benzyl-2-C-benzyloxymethyl-6-O-tert-butyldimethylsilyl-2-deoxy-D-gluco-δ-lactam 

Downstream Products

• 682771-71-7 6-acetamido-N-benzyl-3,4-di-O-benzyl-2-C-benzyloxymethyl-1,2,5,6-tetradeoxy-1,5-imino-D-glucitol 
• 682771-70-6 6-amino-N-benzyl-3,4-di-O-benzyl-2-C-benzyloxymethyl-1,2,5,6-tetradeoxy-1,5-imino-D-glucitol 
• 682771-69-3 6-azido-N-benzyl-3,4-di-O-benzyl-2-C-benzyloxymethyl-1,2,5,6-tetradeoxy-1,5-imino-D-glucitol 

Relevant academic research and scientific papers

Design and synthesis of 2-acetamidomethyl derivatives of isofagomine as potential inhibitors of human lysosomal β-hexosaminidases

As part of a program towards the development of specific inhibitors of human lysosomal β-hexosaminidase for use as chemical chaperones in therapy of GM2 gangliosidosis related diseases, the synthesis of 2-acetamidomethyl derivatives of isofagom